Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Uspehi Molekularnoj Onkologii is Scopus-indexed (Q4, CiteScore 0.6). Published by ABV-press Publishing House.
Checked against the index lists dated .
ISSN 2313-805XVerify ISSN ↗2413-3787Verify ISSN ↗
Publisher: ABV-press Publishing House
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | 45 / 57 | 21st | Q4 |
| Biochemistry (medical) | 69 / 78 | 12th | Q4 |
| Genetics (clinical) | 90 / 100 | 10th | Q4 |
| Cancer Research | 216 / 233 | 7th | Q4 |
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2019–present, best quartile Q4, CiteScore 0.6.
Uspehi Molekularnoj Onkologii is Q4 in Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (rank 45 of 57), Q4 in Biochemistry (medical) (rank 69 of 78) and Q4 in Genetics (clinical) (rank 90 of 100), by CiteScore 2025. It is ranked in 4 subject areas in all.
Uspehi Molekularnoj Onkologii is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 0.6, quartile Q4, 21st percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.126, quartile Q4, with an H-index of 4.
Uspehi Molekularnoj Onkologii is published by ABV-press Publishing House. Its print ISSN is 2313-805X and its online ISSN is 2413-3787.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
No — it is not registered as an open-access journal in DOAJ or Scopus.
Uspehi Molekularnoj Onkologii has an h-index of 8 and a 2-year mean of 0.49 citations per paper (OpenAlex). Its Scopus CiteScore is 0.6, quartile Q4. On 2-year citations it ranks #36 of 52 Scopus journals in Pharmacology, Toxicology and Pharmaceutics (miscellaneous).
Uspehi Molekularnoj Onkologii published 43 papers in 2025; its busiest recent year was 2023 with 47. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2024–2026), authors are most often from Russia (94.3%), Ukraine (2%) and Belarus (1.5%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.